You are here: Home » PTI Stories » National » News
Business Standard

Suven Life gets product patents from New Zealand, Norway

Press Trust of India  |  New Delhi 

Sciences today said it has been granted a product by and each corresponding to a (NCE) for treatment of associated with

These patents are valid till 2034 and 2027, respectively, the company said in a BSE filing.

"We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for with high unmet medical need with a huge market potential globally," said.

The granted claims of patents are being developed as therapeutic agents useful in associated with like Alzheimer's disease, (ADHD), Huntington's disease, and schizophrenia, it added.

Sciences shares were trading 1.86 per cent up at Rs 183.80 on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, May 22 2018. 11:55 IST